Forward Pharma A/S

📍 Hellerup, Denmark🗓 Founded 2005👥 4 employees💰 Last funded Jun 2015
Biotechnology
LinkedIn
Forward Pharma A/S was a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The company completed a voluntary solvent liquidation in 2025.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2005
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Forward Pharma A/S?
Forward Pharma A/S has 1 investors on record on gritt.io.
When did Forward Pharma A/S last raise funding?
The most recent investment in Forward Pharma A/S recorded on gritt.io was in June 2015.
When was Forward Pharma A/S founded?
Forward Pharma A/S was founded in 2005.
What industry is Forward Pharma A/S in?
Forward Pharma A/S operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Forward Pharma A/S based?
Forward Pharma A/S is headquartered in Hellerup, Denmark.